STOCK TITAN

AEON Biopharma: Ikarian reports 9.9% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

AEON Biopharma, Inc. (AEON) is the subject of a Schedule 13G reporting 7,362,438 shares of Class A common stock, or 9.9%, as beneficially owned by each reporting person, Ikarian Capital, LLC and Neil Shahrestani. The securities are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital manages the fund and accounts, and Shahrestani may be deemed to own the securities indirectly through his control of Ikarian Capital.

The reported amount includes 2,181,063 shares acquirable within 60 days under warrants. Conversion is restricted if it would cause the reporting persons’ beneficial ownership to exceed 9.99% of outstanding shares. The percentage calculation uses 73,698,083 shares, including warrant shares, and cites 71,517,020 shares outstanding as of October 30, 2026.

Beneficial ownership 7,362,438 shares Reported by each reporting person; includes shares acquirable under warrants.
Percentage of class 9.9% Reported beneficial ownership percentage.
Warrant shares 2,181,063 shares May be acquired within 60 days; conversion is subject to a 9.99% restriction.
Conversion restriction threshold 9.99% Restriction applies if conversion would cause beneficial ownership to exceed this percentage of outstanding shares.
Shares outstanding 71,517,020 shares As of October 30, 2026, as cited in the ownership percentage calculation.
Percentage calculation base 73,698,083 shares Includes the warrant shares and the 71,517,020 shares outstanding as of October 30, 2026.
beneficial ownership regulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
separately managed accounts financial
"the Fund and certain separately managed accounts"
A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.
warrants financial
"shares ... may be acquired ... pursuant to warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
investment discretion financial
"through the investment discretion it has over the Fund"
shared voting power regulatory
"Shared Voting Power 7,362,438.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 7,362,438.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AEON shares did Ikarian Capital and Neil Shahrestani report owning?

Each reported beneficial ownership of 7,362,438 shares, or 9.9% of AEON’s Class A common stock. The securities are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.

How do warrants affect Ikarian Capital’s reported AEON ownership?

The reported amount includes 2,181,063 shares acquirable within 60 days under warrants. Conversion is restricted if it would cause the reporting persons’ beneficial ownership to exceed 9.99% of outstanding shares. The percentage calculation uses 73,698,083 shares, including warrant shares, and cites 71,517,020 shares outstanding as of October 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





00791X209

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent Class A common stock, $0.0001 par value per share ("Common Stock") of AEON Biopharma, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figures in Items 6, 8, 9, and 11 include 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock of the Issuer then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock of the Issuer. (3) The figure in Item 11 is based upon 73,698,083 shares of Common Stock of the Issuer outstanding, which includes the 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 71,517,020 shares of Common Stock of the Issuer outstanding as of October 30, 2026, as disclosed in the Issuer's Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on November 2, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent Common Stock of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figures in Items 6, 8, 9, and 11 include 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock of the Issuer then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock of the Issuer. (3) The figure in Item 11 is based upon 73,698,083 shares of Common Stock of the Issuer outstanding, which includes the 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 71,517,020 shares of Common Stock of the Issuer outstanding as of October 30, 2026, as disclosed in the Issuer's Form 8-K filed with the SEC on November 2, 2026.


SCHEDULE 13G



Ikarian Capital, LLC
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:11/16/2026
Neil Shahrestani
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith).

Keep reading